Performance of the Eversense versus the Free Style Libre Flash glucose monitor during exercise and normal daily activities in subjects with type 1 diabetes mellitus

Marion Fokkert 1, 2,3, Peter R van Dijk 4, 5, Mireille A Edens 6, 7, Alberto Diez Hernández 3, Robert Slingerland 1, Rijk Gans 2, Elías Delgado Álvarez 5, 6, Henk Bilo 3

To cite: Fokkert M, van Dijk PR, Edens MA, et al. Performance of the Eversense versus the Free Style Libre Flash glucose monitor during exercise and normal daily activities in subjects with type 1 diabetes mellitus. BMJ Open Diab Res Care 2020;8:e001193. doi:10.1136/bmjdrcc-2020-001193

ABSTRACT

Introduction Accurate blood glucose measurements are important in persons with diabetes during normal daily activities (NDA), even more so during exercise. We aimed to investigate the performance of fluorescence sensor-based and glucose oxidase-based interstitial glucose measurement during (intensive) exercise and NDA.

Research design and methods Prospective, observational study in 23 persons with type 1 diabetes when mountain biking for 6 days, followed by 6 days of NDA. Readings of the Eversense (fluorescence-based continuous glucose monitoring (CGM); subcutaneously implanted) and of the Free Style Libre (FSL; glucose oxidase-based flash glucose monitoring (FGM); transcutaneously placed) were compared with capillary glucose levels (Free Style Libre Precision NeoPro strip (FSLCstrip)).

Results Mean average differences (MAD) and mean average relative differences (MARD) were significantly different when comparing exercise with NDA (reference FSLCstrip); Eversense MAD 25±19 vs 17±6 mg/dL (p<0.001); MARD 17±6 vs 13±6% (p<0.01) and FSL MAD 32±17 vs 18±8 mg/dL (p<0.01); MARD 20±7 vs 12±5% (p<0.001).

When analyzing the data according to the Integrated Continuous Glucose Monitoring Approvals (class II–510(K) guidelines), the overall performance of interstitial glucose readings within 20% of the FSLCstrip during exercise compared with NDA was 69% vs 81% for the Eversense and 59% vs 83% for the FSL, respectively. Within 15% of the FSLCstrip was 59% vs 70% for the Eversense and 46% vs 71% for the FSL.

Conclusions During exercise, both fluorescence and glucose oxidase-based interstitial glucose measurements (using Eversense and FSL sensors) were less accurate compared with measurements during NDA. Even when acknowledging the beneficial effects of CGM or FGM, users should be aware of the risk of diminished accuracy of interstitial glucose readings during (intensive) exercise.

INTRODUCTION

Regular exercise by persons with diabetes mellitus (DM) contributes to physiological and health benefits on the short and long term.1–3 Maintaining acceptable glucose concentrations during sports activities is challenging, however. The more intense the sport activity and the more extreme the conditions, the larger the challenge of balancing energy intake and insulin use. Therefore, particularly during exercise, timely and accurate blood glucose readings are of importance to enhance chances on good metabolic control, allowing maximal performance.

During strenuous circumstances, an alternative to capillary self-measurement of blood glucose (SMBG) levels performed is
interstitial glucose measurements. At present, real-time continuous glucose monitoring (rt-CGM) and flash glucose monitoring (FGM) are available as methods for interstitial glucose measurements. If used appropriately, with rt-CGM the user often only needs to calibrate the sensor at some time points daily and being able to act and react on alarms preset at certain cut-off points. In contrast, FGM users use a factory-calibrated sensor, which with the presently available version in The Netherlands needs scanning for obtaining the required information.4

Some authors report qualitatively comparable glucose results of rt-CGM and FGM,5 although others observed differences in accuracy.6 However, these comparative studies are virtually always done under routine or standardized clinical circumstances. With such standardized testing, it can be assumed that factors such as interstitial fluid dynamics and interstitial glucose concentrations will behave more or less in a stable pattern during the testing periods. In contrast, real-life (intensive) exercise most likely will lead to more frequent and profound changes in interstitial fluid dynamics and thus in interstitial glucose concentration.7 Therefore, performance of interstitial glucose measurements might be quite different during intensive exercise conditions as compared with a performance during normal daily activities (NDA). Furthermore, depending on the technique used to measure interstitial glucose concentrations, the change in interstitial fluid dynamics might also affect reading outcomes differently.

In an earlier study, we found that during NDA and standardized tests FGM reading showed lower glucose concentrations than actually present with capillary measurements in the lower ranges, and higher than found in the higher ranges.8 In contrast, FGM performance proved to be different during intensive exercise in a real-life setting, showing comparatively higher glucose readings than actually present, but also less accuracy throughout the whole measurement spectrum.9 The rt-CGM performance during exercise in that study also was less accurate than hoped for. Both the FGM and rt-CGM devices used in that study used a glucose oxidase based method for measuring glucose.10 11

Recently, an implantable rt-CGM device has been introduced (Eversense), using fluorescence-based glucose measurement technique,12 with an accuracy comparable to other rt-CGM devices.13 The Eversense is an implantable rt-CGM device, needs calibrating twice daily, and ideally functions for 6 months. The Free Style Libre (FSL) FGM system has a translucent probe, is factory calibrated and functions for 14 days.

Given the importance of reliable glucose measurements during intensive exercise, we aimed to compare in a real-life setting the accuracy of two interstitial devices that use both a different method (glucose oxidase based vs fluorescence based) to measure glucose in persons with type 1 diabetes mellitus (T1DM). Furthermore, since differences in accuracy may differ depending on the circumstances and activity level,14 measurements were also performed during a period of NDA with no sports activities in the week after the mountain biking.

**RESEARCH DESIGN AND METHODS**

**Study design**

This was a prospective, observational study. The aim was to compare two different methods for interstitial glucose measurements: fluorescence based (using the Eversense) versus glucose oxidase based (using FSL) in two consecutive time periods, with first a 6-day period of intensive exercise, followed by a 6-day period of NDA.

Capillary glucose measurements were performed with Precision Neo Pro strips (Free Style Libre Capillary glucose measurement strip (FSLstrip)).8 In earlier research, this capillary measurement strip was verified to be closely comparable with National Institute of Standards and Technology (NIST) standards to the gold reference method (y=0.974x−0.294, correlation 0.995).8 15 Therefore, it was decided to use the results of the FSLstrip as the reference values.

**Setting and participants**

This study was performed during the Bas van de Goor Foundation ‘webike2changediabetes’ challenge in September 2018 and in the week after the challenge (NDA, no sports activities). The Bas van de Goor Foundation is a non-profit organization that aims to promote sports and exercise in persons with DM. During the current challenge, a combined team of 29 persons with 27 T1DM and 2 type 2 diabetes mellitus from Spain and the Netherlands mountain biked in the Sierra Nevada, over a total distance of 263 km and a variable amount of altitude meters spread over the days (in total minimal 4753 up to 11000 m) https://bvdgf.org/evenementen/evenement/27041/webike2changediabetes-2018/. The maximum altitude reached was 3398 m,16 but only for a short period of time. All participants in the Bas van de Goor Foundation challenge ‘webike2changediabetes’ in September 2018 were asked to participate in the study.

**Procedures**

Eventually, 23 participants with T1DM of total of the 27 participants agreed to be included in the study. After obtaining written informed consent, baseline characteristics were collected before and at start of the challenge. Eversense devices were implanted in the back of the upper arm, at one center in The Netherlands and several centers in Spain in the month of August 2018, according to the operating instructions, and by certified care professionals. FSL were inserted prior (>12 hours) to the challenge on the back of the opposite upper arm. The algorithm used to assess the readings of the Eversense was the same as in the Precise I study,15 (being the initial Eversense algorithm; since then, a new algorithm has been implemented) for the FSL the FSL’s first glucose known algorithm was used with the first available version of the FSL without the alarm functions as present in the FSL 2 version.
Participants were asked to perform a total of (at least) 7 SMBGs per day using FSLCstrip test strips with the blood glucose meter incorporated in the FSL reader. Participants scanned the glucose value with the FSL reader, performed a finger prick and finished with another scan with the FSL reader. The maximum time allowed between the two scans was 2 min. Participants were asked to perform extra SMBGs if necessary, for instance, when experiencing symptoms related to hypoglycemia. Eversense and FSL readings, taken with maximal 2 min of the capillary FLS Cstrip measurement, were considered to be valid for comparison. For the Eversense, two FSLCstrip measurements per day were used for the calibration of the Eversense: these two calibration measurements were not included in the analysis comparing the readings of the both interstitial measuring devices and the FSLCstrip.

Outcomes

Primary outcome of the present study was the accuracy of both methods for interstitial glucose measurements fluorescence based (Eversense) versus glucose oxidase (FSL) with the FLS Cstrip during exercise and during NDA. Results related to accuracy were (primarily) assessed by calculating mean absolute differences (MAD), mean absolute relative differences (MARD). Since control frequency was different between participants, MAD and MARD were calculated per person, not per glucose measurement (ie, for each participant, MAD and MARD was calculated for each measurement, and the individual MADs and MARDs were translated into a mean MAD and MARD for each participant, both for the exercise period and the NDA period.

Secondary outcomes included the accuracy of the interstitial readers when assessed according to the cut-off points as formulated in the Integrated Continuous Glucose Monitoring Approvals (class II–510(K) guidelines) (ICGMA guidelines) and comparisons between exercise and NDA with the Parkes error grid analysis. For the latter purpose, Eversense, FSL and FSLCstrip readings in the two defined periods were fitted on the error grids as described by Parkes et al.

Statistical methods

Data were expressed as number (percentage), mean (SD) or median (IQR) for normally distributed and non-normally distributed data, respectively. Normality was examined with Q-Q plots.

Concerning measurements maximally 2 min apart, the MAD and MARD between the Eversense and FSL were compared. For comparison of the exercise condition and NDA (subsequent weeks), data were analyzed as summary measure, that is, the average MAD and MARD for each participant during both conditions was used for analysis. Data were tested using the paired t-test.

The comparison with the cut-off points as formulated in the ICGMA guidelines was purely descriptive.

For risk assessment of possible differences between interstitial-based glucose values versus FSLCstrip measurements, a Parkes error grid analysis, with percentage of measurements within consensus error grid zones, was performed. Values in zones A and B are deemed clinically acceptable, whereas those in zones C, D and E are considered potentially unsafe.

Where applicable, a significance level of 5% was used. Analyses were performed using SPSS V.25.0 (IBM SPSS Statistics, Armonk, New York, USA) and Microsoft Excel Analyse-It (2010).

RESULTS

Baseline characteristics of the 23 study participants with T1DM are shown in table 1.

In general, Eversense readings were significantly lower both during exercise and NDA (except for the hypoglycemic ranges where small numbers of pairs were present (n=61 and n=49)), whereas the FSL readings were significantly higher during exercise, but not different from the FSLCstrip readings during NDA.

Table 2 shows the differences in glucose readings in total, and in the ranges ≤70, 71–180 and >180 mg/dL.

In general, Eversense readings were significantly lower both during exercise and NDA (except for the hypoglycemic ranges where small numbers of pairs were present (n=61 and n=49)), whereas the FSL readings were significantly higher during exercise, but not different from the FSLCstrip readings during NDA.

In table 3, results are shown of 22 of the 23 participants. In one participant, the FSL sensor came loose from the arm (impacted) during the NDA week, which precluded inclusion of this one patient in the analysis. MADs and MARDs of Eversense and FSL compared with FSLCstrip were significantly higher during exercise compared with NDA; Eversense: MAD 25±10 vs 17±6 mg/dL (p<0.001).

### Table 1 Baseline characteristics

| Characteristic                  | n=23  |
|--------------------------------|-------|
| Age (years)                    | 43 (18–56) |
| Female (%)                     | 3 (13) |
| HbA1c (mmol/mol)               | 52 (36–76) |
| Diabetes duration (years)      | 17 (4–27) |
| MDI/CSII                       | 14/9  |

Data are presented as n (%) or median (range).

CSII, Continuous Subcutaneous Insulin Infusion; HbA1c, hemoglobin A1c; MDI, Multiple Daily Injections.
and MARD 17±6 vs 13%±6% (p=0.004); FSL: MAD 32±17 vs 18±8 mg/dL (p=0.002) and MARD 20±7 vs 12%±5% (p<0.001).

When analyzing the data according to the ICGMA guidelines, performance during the exercise week does not reach the agreed on cut-off levels in either category of glucose levels or in total (table 4).

This failure to reach those levels is especially pronounced with the stricter cut-off levels. The situation improves when assessing performance during the NDA period.

When assessing the performance of the Eversense CGM during exercise compared with the FSLCstrip, 98.3% of the comparisons fell within zones A and B (73.2% and 25.1%, respectively) of Parkes error grid analysis, with the slope following closely the x=y line: y=0.101x−9.88, correlation 0.883 (figure 1A). In the NDA week, the Eversense versus FSLCstrip comparison showed 98.8% of the comparison within zones A and B (81.9% and 16.9%, respectively), again with the slope closely following the x=y line: y=0.96x−0.11, correlation 0.920; figure 1B). Assessing the comparative readings during daily activities in zone B, the Eversense CGM tends to show slightly lower concentrations than measured by capillary assessment, this in contrast to the observations with the FSL.

During exercise, only few comparative readings of FSL compared with FSLCstrip were outside the zones A and B, 98.2% (73.9% and 24.3%, respectively), with a majority (84%) of the B readings in the upper B region (figure 2A). The slope of the comparison line was 1.21, which allowed the conclusion, especially with higher glucose concentrations, that the flash FSL tends to show higher readings compared with capillary measurements (y=1.21x−10.13, correlation 0.917). FSL measurements during NDA were well correlated to the FSLC measurements, with 99.9% of the points within the zones A and B (87.1% and 12.8%, respectively); the slope was 1.07 (y=1.07x−9.57), with a correlation of 0.937; figure 2B).

### DISCUSSION

In this study we demonstrated that when testing two different interstitial glucose measurement techniques, both the Eversense (fluorescence based) and FSL (glucose oxidase based) are less accurate during a period of exercise compared with a period of NDA. Importantly, differences are notable and relevant in virtually all categories. MAD and MARD during an exercise period are higher than during NDA, allowing the conclusion that both devices show less accuracy during exercise than during NDA. This conclusion is confirmed when measurements are assessed according to the ICGMA guidelines.

It has been shown that a reasonable or even high correlation between interstitial readings and capillary blood glucose concentrations is no guarantee for accuracy, and other measures such as MAD and MARD are needed for interpretation of the true accuracy.

### Table 2 Comparisons at various glucose concentrations of Eversense versus FSL versus FSLCstrip measurements as reference

| Range (mg/dL) | N | FSLCstrip | Eversense | FSL |
|---------------|---|-----------|-----------|-----|
| Exercise      |   |           |           |     |
| ≤70           | 61| 58±10     | 59±15     | 73±17**|
| 71–180        | 544| 125±30   | 117±39**  | 142±43**|
| >180          | 303| 241±53   | 222±59**  | 276±76**|
| Total         | 908| 159±72   | 148±71**  | 182±88**|

Normal daily activity

| Range (mg/dL) | N | FSLCstrip | Eversense | FSL |
|---------------|---|-----------|-----------|-----|
| ≤70           | 49| 59±9      | 68±26*    | 60±13 |
| 71–180        | 504| 127±30   | 122±33**  | 128±39 |
| >180          | 261| 238±47   | 223±51**  | 240±57 |
| Total         | 814| 158±67   | 151±64**  | 160±73 |

2 vs 1 and 3 vs 1.

*P<0.05; **P<0.001.

FSL, Free Style Libre; FSLCstrip, Free Style Libre Precision NeoPro strip;

and MAD 17±6 vs 13%±6% (p=0.004); FSL: MAD 32±17 vs 18±8 mg/dL (p=0.002) and MARD 20±7 vs 12%±5% (p<0.001).

When analyzing the data according to the ICGMA guidelines, performance during the exercise week does not reach the agreed on cut-off levels in either category of glucose levels or in total (table 4).

This failure to reach those levels is especially pronounced with the stricter cut-off levels. The situation improves when assessing performance during the NDA period.

When assessing the performance of the Eversense CGM during exercise compared with the FSLCstrip, 98.3% of the comparisons fell within zones A and B (73.2% and 25.1%, respectively) of Parkes error grid analysis, with the slope following closely the x=y line: y=0.101x−9.88, correlation 0.883 (figure 1A). In the NDA week, the Eversense versus FSLCstrip comparison showed 98.8% of the comparison within zones A and B (81.9% and 16.9%, respectively), again with the slope closely following the x=y line: y=0.96x−0.11, correlation 0.920; figure 1B). Assessing the comparative readings during daily activities in zone B, the Eversense CGM tends to show slightly lower concentrations than measured by capillary assessment, this in contrast to the observations with the FSL.

During exercise, only few comparative readings of FSL compared with FSLCstrip were outside the zones A and B, 98.2% (73.9% and 24.3%, respectively), with a majority (84%) of the B readings in the upper B region (figure 2A). The slope of the comparison line was 1.21, which allowed the conclusion, especially with higher glucose concentrations, that the flash FSL tends to show higher readings compared with capillary measurements (y=1.21x−10.13, correlation 0.917). FSL measurements during NDA were well correlated to the FSLC measurements, with 99.9% of the points within the zones A and B (87.1% and 12.8%, respectively); the slope was 1.07 (y=1.07x−9.57), with a correlation of 0.937; figure 2B).

### Table 3 MAD and MARD of the (n=22) Eversense and FSL versus FSLCstrip measurements; glucose in mg/dL; results in mean and SD; reference value FSLCstrip

|          | MAD Normal daily activity (mg/dL) | MARD (mg/dL) | MAD Normal daily activity (%) | MARD (%) |
|----------|----------------------------------|--------------|-------------------------------|----------|
| Eversense| 25±10                            | 17±6**       | 17±6                          | 13±6*    |
| FSL      | 32±17                            | 18±8*        | 20±7                          | 12±5**   |

Exercise versus normal daily activity.

*P<0.01; **P<0.001.

FSL, Free Style Libre; FSLCstrip, Free Style Libre Precision NeoPro strip; MAD, mean average differences; MARD, mean average relative differences.
According to our findings, during periods of exercise the FSL tends to show higher than actual glucose concentrations, while the Eversense does show an opposite tendency. Whether these differences are caused by different algorithms translating the sensor signals into a glucose concentration value, or by another cause, is not known.

Taken together, this means that using interstitial glucose measurements during exercise is less accurate, which in its turn can have relevant consequences when inaccurate readings lead to wrong decisions. Users quickly learnt to handle the—sometimes—contradictory outcomes, often by assessing the trend information more than point measurements and controlling the readings through a capillary measurement when there was reason to doubt the result. Since we did not study these aspects, no formal conclusions can be drawn with regard to these aspects.
Metabolism

Providing a definitive explanation for the apparent different behavior of interstitial glucose sensors during NDA and during intensive exercise is complex. The more intensive the exercise, the more circulatory, tissue and interstitial changes will occur. Rate of glucose change and interstitial fluid flow will increase, possibly influencing the amount of glucose passing the FSL sensor per time unit. One possible explanation, at least partly, for the increased MARD during activity may be that the changes in interstitial readings lag behind the changes in blood glucose during prolonged aerobic exercise, which will contribute to an increase in MARD during exercise, as shown by Zaharieva et al. Others possible causes include outside and skin temperature, weather conditions, intensity of exercise and degree of insulation caused by clothing. Furthermore, since nobody will exercise 24 hours per day, periods of exercise will be alternated with periods of rest and less efforts during the exercise week. This also will have its influences.

Our study does have strengths and limitations. From a user’s point of view, testing in a real-life setting yields results, which often will be more applicable and recognizable than results obtained in a laboratory setting. Even if results during real life use are not as accurate as hoped for, studies like ours help to recognize the limitations and pitfalls of the use of rt-CGM and FGM under various circumstances.

One limitation of this study is our failure to ask the participants to exactly note down their actual time biking. Therefore, we could not perform a subanalysis of data acquired during the 24 hours of the exercise days during the exercise itself, and during the period(s) outside the exercise hours. Speculating on whether that would have influenced the results, theoretically, this difference in oxygen availability might influence interstitial oxygen availability, which in turn might affect glucose oxidation rate. During our study, time at altitude was limited; furthermore, one has to keep in mind that by mountain biking at altitude the primary demand will be to adjust breathing frequency and intensity according to the skeletal and cardiac muscle oxygen needs. Since this will be different for each individual, we felt it impossible to introduce a reliable correction for that factor. In addition, the influence of, among others, differences in environmental temperature, effects of altitude and concomitant decrease in partial oxygen pressure and humidity and participants’ hydration were not systematically assessed. Therefore, we could not correct for the possible influence of these factors. In a next study, we will need to combine FGM and rt-CGM registrations with additional devices to measure these factors. That would also allow a more detailed analysis of the influence of exercise proper, the resting periods during the exercise week (including sleeping) and a separate period of NDA.

Of notice, during the present study the first version of the FSL was used, thus missing the hypoglycemia alarm incorporated in the more recent FSL version.

Another major limitation is of course the use of a capillary glucose measurement using a glucose strip as the comparative method instead of, for example, a Yellow Springs Analyzer or glucose hexokinase measurement. In our opinion, the use of a Precision Neo Pro as ‘gold standard’ is justifiable, since this strip is aligned with NIST standards to the gold reference method. A further limitation is that the majority of the persons included in this study were male, possibly limiting the generalizability of our results.

CONCLUSIONS

During exercise compared with daily life activities, interstitial glucose readings with both the Eversense (fluorescence based) and the FSL (glucose oxidase based) were less accurate, often with clinically relevant differences,
compared with capillary measurements. This phenomenon was present throughout the whole range of glucose concentrations.

Even when acknowledging the limitations of a study in a real-life setting, users and healthcare providers should be aware of this and be given proper education with regard to the described phenomenon.

Although we did not formally test the described shortcomings during exercise, the vast majority of users consider using any form of CGM as a valuable tool for glucose monitoring, and gladly accept a lesser performance in exchange for more detailed information on glucose levels and glucose trends.

**Author affiliations**

1Department of Clinical Chemistry, Isala, Zwolle, NA, The Netherlands
2Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
3Diabetes Research Center, Isala, Zwolle, NA, The Netherlands
4Department Innovation and Science, Isala, Zwolle, NA, The Netherlands
5Sección de Endocrinología, Hospital del Bierzo, Ponferrada, Castilla y León, Spain
6Sección de Diabetes, Universidad de Oviedo, Oviedo, Asturias, Spain
7Sección de Diabetes, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain

**Acknowledgements**

The authors would like to thank the participants for participating in the study and Nicole Spelie for data collection.

**Contributors**

MF wrote protocol, did the practical examination, researched data, wrote manuscript, contributed to discussion. PhD researched data, contributed to discussion, reviewed/editied manuscript. MAE, RS and RG contributed to discussion, reviewed/editied the manuscript. ADH and EDA did the practical examination, contributed to discussion, reviewed/editied manuscript. HB co-wrote protocol, contributed to discussion, reviewed/editied manuscript.

**Funding**

This study was an investigator initiated study. Funding was made available by de Bas van de Goor foundation and Eversense materials were made available by Roche. MF and HB are the guarantors for the presented work.

**Competing interests**

None declared.

**Patient consent for publication**

Not required.

**Ethics approval**

This study was approved by the Medical Ethical committees in Spain (Hospital Universitario Centro de Asturias; 163/18) and The Netherlands (Isala Hospital; NL66388.075.18/180603) and registered in the Dutch trial register (www.trialregister.nl number NL7133). All participants gave written informed consent prior to the start of the study.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data availability statement**

Data are available on reasonable request. Nine hundred seventy data sets are available from Eversense and FSL with FSLScstrip comparison in the exercise week, and, subsequently, 896 data sets available for the normal daily activity week 1 year after publication.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.

**ORCID iDs**

Marion Fokkert http://orcid.org/0000-0002-4687-1157

Peter R van Dijk http://orcid.org/0000-0002-9702-6551

Mireille A Edens http://orcid.org/0000-0001-5449-5035

Elia Delgado Álvarez http://orcid.org/0000-0001-6114-9712

**REFERENCES**

1. Lopes Souto D, Paes de Miranda M. Physical exercices on glycemic control in type 1 diabetes mellitus. *Nutr Hosp* 2011;26:425–9.

2. Lukács A, Barkai L. Effect of aerobic and anaerobic exercises on glycemic control in type 1 diabetic youths. *World J Diabetes* 2015;6:534.

3. Ishiguro H, Kodama S, Horikawa C, *et al*. In search of the ideal resistance training program to improve glycemic control and its indication for patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *Sports* 2016;6:67–77.

4. Heinemann L, Freckmann G. CGM versus FGM; or, continuous glucose monitoring is not flash glucose monitoring. *J Diabetes Sci Technol* 2016;5:9:947–50.

5. Bonora B, Maran A, Cicilliò S, *et al*. Head–To-Head comparison in the exercise week, and, subsequently, 896 data sets available for type 1 diabetes. *J Endocrinol Invest* 2016;39:1391–9.

6. Aberer F, Hajnsek M, Rumpler M, *et al*. Evaluation of subcutaneous glucose monitoring systems under routine environmental conditions in patients with type 1 diabetes. *Diabetes Obes Metab* 2017;19:1051–5.

7. Moser O, Yardley JE, Bracken RM. Intrastitial glucose and physical exercise in type 1 diabetes: integrative physiology, technology, and the gap In-Between. *Nutrients* 2018a;10:93.

8. Fokkert MJ, van Dijk PR, Edens MA, *et al*. Performance of the FreeStyle Libre flash glucose monitoring system in patients with type 1 and 2 diabetes mellitus. *BMJ Open Diabetes Res Care* 2017;5:e000320.

9. Fokkert MJ, van Dijk PR, Edens MA, *et al*. Performance of continuous glucose monitoring devices during intensive exercise conditions in people with diabetes: the Mont blanc experience. *Diabet Med* 2020;37:1204–5.

10. Bruen D, Delaney C, Florea L, *et al*. Glucose sensing for diabetes monitoring: recent developments. *Sensors* 2017;17:1866.

11. Wang H-C, Lee A-R. Recent developments in blood glucose sensors. *J Food Drug Anal* 2015;23:191–200.

12. Mortelaro M, DeHennis A. Performance characterization of an abiotic and fluorescnet-based continuous glucose monitoring system in patients with type 1 diabetes. *Biosens Bioelectron* 2014;61:227–31.

13. Kroff J, Choudhary P, Neupane S, *et al*. Accuracy and longevity of an implantable continuous glucose sensor in the precise study: a 180-day, prospective, multicenter, pivotal trial. *Diabetes Care* 2017;40:63–8.

14. Biagi L, Bertacci A, Quiros C, *et al*. Accuracy of continuous glucose monitoring before, during, and after aerobic and anaerobic exercise in patients with type 1 diabetes mellitus. *Biosensors* 2018;8:22.

15. TuRFriendland. Goedgekeurde bloedglucometers, 2019. Available: https://www.tuv.com/nl/netherlands/services_nl/product_testing_nl/medical_devices_nl/tested_medical_device.html

16. de Mol P, Krabbe HG, de Vries ST, *et al*. Accuracy of handheld blood glucose meters at high altitude. *PLoS One* 2010;5:e15485.

17. Gang SK, Akturk HK. A new era in continuous glucose monitoring: food and drug administration creates a new category of Factory-Calibrated Nonadjunctive, Interoperable class II medical devices. *Diabetes Technol Ther* 2018;20:391–4.

18. Parkes JL, Stolin SL, Parado S, *et al*. A new consensus error grid to evaluate the clinical significance of inaccuracies in the measurement of blood glucose. *Diabetes Care* 2000;23:1143–8.

19. Zaharieva DP, Turkosy K, McGaugh SM, *et al*. Lag time remains with newer real-time continuous glucose monitoring technology during aerobic exercise in adults living with type 1 diabetes. *Diabetes Technol Ther* 2019;21:313–21.

20. Baille Lab. Altitude air pressure calculator. Available: https://bailielab.net/criticalCare/air_pressure/